Table 2.
Recent reported HCV prevalence in hemodialysis patients
| Country | N | Year of testing | HCV prevalence (%) | Source |
|---|---|---|---|---|
| Australia-New Zealand | 393 | 2012 | 3.8 | DOPPS 5147 |
| Belgium | 485 | 2012 | 4.0 | DOPPS 5147 |
| Brazil | 798 | 2011 | 8.4 | Rodrigues de Freitas148 |
| Canada | 457 | 2012 | 4.1 | DOPPS 5147 |
| China | 1189 | 2012 | 9.9 | DOPPS 5147 |
| Cuba | 274 | 2009 | 76 | Santana149 |
| Egypt | – | 2007–2016 | 50 | Ashkani-Esfahan149a |
| France | 501 | 2012 | 6.9 | DOPPS 4147 |
| Germany | 584 | 2012 | 4.5 | DOPPS 5147 |
| Gulf Cooperation Council | 910 | 2012 | 19.3 | DOPPS 5147 |
| India | 216 | 2012 | 16 | NephroPlus |
| 1050 | 2013 | 11 | ||
| 3068 | 2014 | 8 | ||
| Iran | – | 2006–2015 | 12 | Ashkani-Esfahan149a |
| Iraq | – | 2008–2015 | 20 | Ashkani-Esfahan149a |
| 7122 | 2015 | 10 | ||
| 7673 | 2016 | 9 | ||
| Italy | 485 | 2012 | 11.5 | DOPPS 5147 |
| Japan | 1609 | 2012 | 11.0 | DOPPS 5147 |
| Jordan | – | 2007–2015 | 35 | Ashkani-Esfahan149a |
| Lebanon | 3769 | 2010–2012 | 4.7 | Abou Rached150 |
| Libya | 2382 | 2009–2010 | 31.1 | Alashek151 |
| Nigeria | 100 | 2014 | 15 | Ummate152 |
| Palestine | – | 2010–2016 | 18 | Ashkani-Esfahan149a |
| Romania | 600 | 2010 | 27.3 | Schiller153 |
| Russia | 486 | 2012 | 14.0 | DOPPS 5147 |
| Saudi Arabia | – | 2007 | 19 | Ashkani-Esfahan149a |
| Senegal | 106 | 2011 | 5.6 | Seck154 |
| Syria | – | 2009 | 54 | Ashkani-Esfahan149a |
| Spain | 613 | 2012 | 8.9 | DOPPS 5147 |
| Sweden | 426 | 2012 | 6.0 | DOPPS 5147 |
| Turkey | 383 | 2012 | 7.0 | DOPPS 5147 |
| United Kingdom | 397 | 2012 | 4.6 | DOPPS 5147 |
| United States | 2977 | 2012 | 7.3 | DOPPS 5147 |
DOPPS, Dialysis Outcomes and Practice Patterns Study; HCV, hepatitis C virus.